Comparing stem cell transplant plus car-t therapy for multiple myeloma
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial compares two treatments for newly diagnosed multiple myeloma: standard stem cell transplant (ASCT) alone versus ASCT followed by CAR-T cell therapy. CAR-T uses your own immune cells to target and kill myeloma cells, which may improve outcomes after transplant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have been diagnosed with multiple myeloma (a blood cancer) and are expected to live more than 3 months.
- You are healthy enough to receive a stem cell transplant, and your liver function is within normal limits.
- You are able to care for yourself (Karnofsky performance status above 50%).
- You are not pregnant or planning to become pregnant in the next 6 months.
- You have no severe allergies, especially to a drug called interleukin-2 (IL-2).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a new immunotherapy treatment using CAR-T cells for people with newly diagnosed multiple myeloma who cannot have a stem cell transplant. The treatment aims to target and destroy myeloma cells that have BCMA and GPRC5D proteins on their surface.
This trial compares two approaches after initial therapy for newly diagnosed multiple myeloma: a T-cell engager (elranatamab) versus a stem cell transplant. The goal is to see which provides better control of the disease, using sensitive MRD testing to guide further treatment.
This study tests a new treatment called CAR-T cell therapy given after your own stem cell transplant. It aims to improve the response for multiple myeloma, a type of blood cancer, and is for patients who did not get a complete response after initial chemo or who have high-risk features.
This trial tests a new CAR-T cell therapy that targets FcRL5 on myeloma cells. It's for people whose myeloma has come back or stopped responding to other treatments, including stem cell transplant.
This trial tests a new kind of CAR-T cell therapy (called APRIL-BAFF-Bicephali CAR-T) for people with multiple myeloma that has come back or not responded to treatment. It aims to see if this therapy is safe and can help when other treatments have stopped working.
This study compares two treatments for newly diagnosed multiple myeloma: CAR-T cell therapy and a stem cell transplant. It aims to see which one works better for patients who are eligible for a stem cell transplant.
Hear when a new Multiple Myeloma, Newly Diagnosed trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.